Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioSante Pharmaceuticals to Present at the Rodman & Renshaw

Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Stephen M. Simes, the company's president and chief executive officer, will present a BioSante corporate and clinical overview at the Acumen BioFin Rodman and Renshaw Annual Healthcare Conference, taking place at the New York Palace Hotel in New York City, from November 5 to 7, 2007. Mr. Simes will present on November 5, 2007 at 4:05 p.m. local time.

BioSante Pharmaceuticals to Present at the Rodman & Renshaw

LINCOLNSHIRE, IL | Posted on October 31st, 2007

A live audio webcast of BioSante's presentation may be accessed at http://www.biosantepharma.com/investors/events.html and a replay will be available at the same link for 90 days.

Rodman & Renshaw, a full-service investment bank, is a leading investment banking firm to the biotechnology and pharmaceutical sectors. This conference will feature presentations from over 350 small and medium biotechnology and pharmaceutical companies, to an audience comprised of stock research analysts, institutional money managers, brokers and individual investors, as well as biotechnology and pharmaceutical industry representatives.

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine.

For more information, please click here

Contacts:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316

http://www.mckinneychicago.com

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Shining rings: A new material emits white light when exposed to electricity: New synthetic approach could spark development of other dynamic materials July 24th, 2017

Scientists announce the quest for high-index materials: All-dielectric nanophotonics: The quest for better materials and fabrication techniques July 22nd, 2017

Announcements

High-speed FM-AFM and simulation reveal atomistic dissolution processes of calcite in water July 28th, 2017

Atomic movies may help explain why perovskite solar cells are more efficient: SLAC's ultrafast 'electron camera' captures surprising atomic motions in these next-generation materials July 28th, 2017

Triple-layer catalyst does double duty: Rice, University of Houston produce robust catalyst to split water into hydrogen, oxygen July 28th, 2017

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Phenom-World Launches Phenom Pro and ProX Generation 5 SEMs at Microscopy & Microanalysis Conference USA: The excellent performance in a wide range of applications offers a serious alternative to floor model SEMs July 26th, 2017

Graduate Students from Across the Country Attend Hands-on NanoCamp: Prominent scientists Warren Oliver, Ph.D., and George Pharr, Ph.D., presented a weeklong NanoCamp for hand-picked graduate students across the United States July 26th, 2017

Nanometrics to Announce Second Quarter Financial Results on August 1, 2017 July 14th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project